)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (ZNTL) investor relations material
Zentalis Pharmaceuticals Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Strategic priorities and trial focus
Strategy centers on rapid development of azenosertib for platinum-resistant ovarian cancer with high cyclin E1 expression, prioritizing the DENALI registration trial and the ASPENOVA confirmatory Phase 3 trial.
DENALI Part 2 is enrolling, with dose selection between 300 mg and 400 mg ongoing; final dose selection and trial readout expected by year-end 2026.
ASPENOVA Phase 3 trial mirrors DENALI eligibility, is randomized against standard-of-care, and includes an adaptive dose confirmation arm to accelerate timelines.
Biomarker-driven patient selection uses a validated IHC assay for cyclin E1, with about 50% of eligible patients expected to be positive.
Prioritization remains on ovarian cancer, with other indications or combinations considered secondary and dependent on resource availability.
Clinical profile and differentiation
Azenosertib is an oral, non-chemo option, offering a differentiated profile from ADCs and chemotherapy, targeting a specific biomarker-defined population.
Demonstrates a favorable tolerability and safety profile, with low rates of high-grade neutropenia and manageable GI side effects.
Data-driven clinical oversight and proactive site support are used to optimize safety and management during trials.
Dose selection is based on overall risk-benefit, response rate, and PKPD modeling, with both doses showing similar tolerability.
Efficacy bar for accelerated approval is around 30% ORR and 5–6 months duration of response, with current data exceeding these thresholds.
Trial design and regulatory strategy
DENALI is a single-arm trial for accelerated approval, while ASPENOVA is a randomized controlled trial, both using the same biomarker criteria.
Adaptive design in ASPENOVA allows for rapid initiation and dose confirmation, minimizing delays between trials.
Regulatory engagement has aligned trial designs with FDA preferences, supporting a clear path for both accelerated and full approval.
Changes in eligibility criteria between DENALI parts include prospective biomarker selection and limits on prior lines of therapy.
Cross-trial evidence suggests cyclin E high expressors have poorer prognosis, supporting the need for targeted therapy.
Impact of DENALI dose selection on adoption
Azenosertib's niche amid ADC competition
Criteria for future assets beyond azenosertib
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Zentalis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
Zentalis Pharmaceuticals
Next Zentalis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Zentalis Pharmaceuticals Inc., operating under the ticker ZNTL on the NASDAQ, is a clinical-stage biopharmaceutical company with a dedicated focus on the discovery and development of small molecule therapeutics aimed at various cancer types. Its pipeline includes a variety of compounds in different stages of clinical trials, targeting key biological pathways in cancer. Zentalis Pharmaceuticals is headquartered in NYC and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage